Company Description
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions.
In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers.
Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease.
The company was incorporated in 2015 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Bharatt Chowrira |
Contact Details
Address: 6 Tide Street, Suite 400 Boston, Massachusetts 02210 United States | |
| Phone | 617 482 2333 |
| Website | puretechhealth.com |
Stock Details
| Ticker Symbol | PRTC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001782999 |
| CUSIP Number | 746237106 |
| ISIN Number | US7462371060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bharatt M. Chowrira J.D., Ph.D. | Chief Executive Officer and Executive Director |
| Daphne Zohar | Founder, Senior Advisor and Board Observer |
| Dr. Robert S. Langer Jr., Ph.D., ScD | Co-Founder and Non-Executive Director |
| Dr. Eric Elenko Ph.D. | Co-Founder and President |
| Dr. David R. Elmaleh Ph.D. | Co-Founder and Senior Advisor |
| Lauren A. White M.B.A. | Chief Financial Officer |
| Allison Mead Talbot | Senior Vice President of Communications and Head of Investor Relations |
| Charles Sherwood III, J.D., Ph.D. | General Counsel and Company Secretary |
| Spencer Ball | Executive Vice President of Human Resources |
| Aleksandra Filipovic M.D., Ph.D. | Head of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Apr 30, 2025 | 6-K | Report of foreign issuer |
| Apr 7, 2025 | 6-K | Report of foreign issuer |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Dec 16, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | UPLOAD | Filing |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | 6-K | Report of foreign issuer |
| Sep 27, 2024 | 6-K | Report of foreign issuer |